Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs

Journal of Virology

Volumn 76, Issue 6, 2002, Pages 3054-3058

  Van Rij, Ronald P ^a   Visser, Janny A ^a   Van Praag, Rieneke M E ^a   Rientsma, Ronald ^a   Prins, Jan M ^a   Lange, Joep M A ^a   Schuitemaker, Hanneke ^a  

^a CLB Sanquin ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR; ZIDOVUDINE;

ARTICLE; CASE REPORT; COMBINATION CHEMOTHERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; VIREMIA; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS STRAIN;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; COCULTURE TECHNIQUES; DRUG THERAPY, COMBINATION; GIANT CELLS; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; TIME FACTORS; VARIATION (GENETICS); VIRAL LOAD; VIREMIA;

EID: 0036188271     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.6.3054-3058.2002     Document Type: Article

References (27)

1. -T-cell subset contains specialized primed cells
2. Susceptibility of in vitro stimulated PBMC to infection with NSI HIV-1 is associated with levels of CCR5 expression and β-chemokine production
3. + T cell decline
4. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines
5. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
6. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
7. PHYLIP-Phylogeny inference package
8. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
9. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
10. Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy
11. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
12. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiretroviral therapy
13. + T cells
14. HIV-1 rebound after anti-retroviral therapy
15. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy
16. Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection
17. Factors influencing T cell turnover in HIV-1-seropositive patients
18. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals
19. Characterisation of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1
20. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1 patients on potent antiretroviral therapy
21. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
22. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy
23. Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of HIV-1 infection
24. Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1
25. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy
26. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
27. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy